10x Genomics
275 hedge funds and large institutions have $1.5B invested in 10x Genomics in 2024 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 89 increasing their positions, 92 reducing their positions, and 49 closing their positions.
27% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 49
3% more funds holding
Funds holding: 268 → 275 (+7)
0.3% less ownership
Funds ownership: 98.09% → 97.79% (-0.3%)
2% less capital inflows, than outflows
Capital inflows: $286M | Capital outflows: $292M
3% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 92
31% less call options, than puts
Call options by funds: $1.4M | Put options by funds: $2.02M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$51.8M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$28.9M |
| 3 |
D.E. Shaw & Co
New York
|
+$19.2M |
| 4 |
ARK Investment Management
St. Petersburg,
Florida
|
+$18.8M |
| 5 |
Camber Capital Management
Boston,
Massachusetts
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$48.8M |
| 2 |
Morgan Stanley
New York
|
-$40.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.8M |
| 4 |
Soleus Capital Management
Greenwich,
Connecticut
|
-$21.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$12.2M |
TXG Hedge Fund Activity: Q4 2024 in Review
275 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2024, worth a combined $1.5B — down 36% from $2.36B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new TXG positions and 49 closed out — a net gain of 13 holders — while 89 added to existing stakes and 92 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $51.8M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $48.8M sold.
- 275 institutional investors held 10x Genomics (TXG) as of Q4 2024, up from 268 in Q3 2024.
- Funds reported $1.5B of 10x Genomics stock for Q4 2024, down 36% quarter-over-quarter.
- 62 funds opened new 10x Genomics positions in Q4 2024 and 49 closed out, a net change of +13 holders.
- The largest 10x Genomics buyer in Q4 2024 was RA Capital Management, an estimated $51.8M added.
- The largest 10x Genomics seller in Q4 2024 was T. Rowe Price Investment Management, an estimated $48.8M sold.
Based on aggregated 13F filings for Q4 2024.